Protara Therapeutics, Inc. (TARA) · Nov 6, 2026 · Earnings
Beat — GAAP EPS $(0.35) vs approximately $(0.37) consensus
Protara’s third-quarter earnings beat the expected loss, but STARBORN-1 enrollment moved into early 2027 as cash declined and trials advance.
Protara is a clinical-stage biotech built around TARA-002 for bladder cancer and lymphatic malformations, with IV Choline Chloride as a second late-stage program. Before this filing, management was targeting several fourth-quarter 2026 milestones, including STARBORN-1 enrollment, ADVANCED-2 enrollment and THRIVE-3 interim data.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net loss (Income Statement) | $(21.688)M | $(13.258)M | |
| Diluted loss per share (Income Statement) | $(0.35) | $(0.31) | $(0.37) |
| R&D expense (Income Statement) | $16.805M | $9.591M | |
| Cash and marketable securities (Balance Sheet) | $143.081M |
The quarter modestly beat the loss consensus, but the underlying burn worsened year over year. Protara posted a diluted loss of $0.35 per share versus a published consensus of approximately $(0.37), a small earnings beat. The more important operating signal is that net loss widened to $21.688 million from $13.258 million, while R&D spending rose to $16.805 million from $9.591 million. 〔0〕
The clearest setback is a delay to the lymphatic-malformation program. Management previously targeted completion of STARBORN-1 enrollment in the fourth quarter of 2026; the new filing moves that milestone to early first quarter 2027. That is not a thesis-breaking delay, but it pushes the next regulatory-enabling step later than the standing plan. 〔1〕
The rest of the near-term development calendar remains intact, with a new manufacturing commitment. Protara still expects to complete the BCG-Unresponsive bladder-cancer cohort by year-end and report THRIVE-3 interim results by year-end. It also agreed after quarter end to purchase manufacturing-related assets from its supply partner, bringing production capability in-house as it prepares for potential TARA-002 commercialization. 〔2〕
Liquidity is still substantial, but the runway is less comfortable than it looked after the prior quarter. Cash and marketable debt securities fell to approximately $143.1 million at September 30 from approximately $161.9 million at June 30, while quarterly net loss reached $21.7 million. The filing does not repeat the prior assertion that existing liquidity funds planned operations into 2028, so the financing picture is less explicitly supported here. 〔3〕
Bottom line: The earnings beat is minor; the more meaningful update is mixed execution, with most milestones on track but STARBORN-1 enrollment slipping into early 2027. The company is advancing its programs and manufacturing setup, yet doing so with rising losses and declining liquidity.
THRIVE-3 interim results, by year-end 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!